Moderna’s first-quarter revenue topped expectations, powered largely by strong international COVID-19 vaccine sales. While the company expects lower-than-anticipated revenue in Q2, it is betting on longer-term growth, targeting a major slice of Europe’s respiratory vaccine market. Its mCombriax launch is planned for 2027, shifting investor focus beyond COVID.
Moderna’s MRNA stock jumped in the US after the pharma company reported results that beat Wall Street expectations. The company posted a loss of $2.52 per share, improving from the prior year and well above the analyst estimate of a $3.96 loss. The surprise miss-to-beat shift sparked buying momentum.
Your news, in seconds
Get the Beige app — every story in 60 words, updated hourly. Free on iOS & Android.
Swipe through stories, personalise your feed, and save articles for later — all on the app.
